Ingmar Hoerr
Ingmar Hoerr is the co-founder of CureVac, a biopharmaceutical company that specializes in mRNA technology for vaccine development. He has been instrumental in the company's evolution from focusing on infectious diseases to concentrating on cancer immunotherapies. Recently, he was in the news following the announcement of CureVac's acquisition by BioNTech, which he views as a positive development for the European biotech landscape, believing it will enhance innovation in mRNA technology.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Germany | 1 | 8.00 | 0.19% | +0% | 83,783,942 | 158,983 | $3,845,000 | 7,296$ |
| Totals | 1 | 83,783,942 | 158,983 | $3,845,000 | 7,296$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Germany:
Ingmar Hoerr is the co-founder of Curevac and has previously served as its CEO.
8
Germany:
Ingmar Hoerr, the founder of Curevac, views the planned acquisition as a positive sign for Europe.
9